Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease
Open Access
- 16 April 2002
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 86 (8), 1333-1335
- https://doi.org/10.1038/sj.bjc.6600243
Abstract
STI571 is a selective tyrosine kinase inhibitor with proven therapeutic potential in malignancies expressing c-kit. A strong c-kit and stem cell factor expression was detected in the Hodgkin and Reed Sternberg cell line L1236, but not in 20 primary cases of classical Hodgkin's disease. Proliferation of L1236 cells was neither affected by addition of stem cell factor nor by neutralising anti-stem cell factor antibodies or STI571. Results suggest that patients with Hodgkin's disease may not benefit from therapy with STI571.Keywords
This publication has 18 references indexed in Scilit:
- Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal TumorNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells.2001
- Activating c-kit Gene Mutations in Human Germ Cell TumorsThe American Journal of Pathology, 1999
- THE ORIGIN OF HODGKIN AND REED/STERNBERG CELLS IN HODGKIN'S DISEASEAnnual Review of Immunology, 1998
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasmNature Genetics, 1996
- Recent Results on the Biology of Hodgkin and Reed-Sternberg cells: II. Continuous Cell LinesLeukemia & Lymphoma, 1993
- Recent Results on the Biology of Hodgkin and Reed-Sternberg Cells. I. Biopsy MaterialLeukemia & Lymphoma, 1992